These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16728702)

  • 1. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
    Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
    Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.
    Scott LM; Scott MA; Campbell PJ; Green AR
    Blood; 2006 Oct; 108(7):2435-7. PubMed ID: 16772604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
    Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
    Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
    Campbell PJ; Griesshammer M; Döhner K; Döhner H; Kusec R; Hasselbalch HC; Larsen TS; Pallisgaard N; Giraudier S; Le Bousse-Kerdilès MC; Desterke C; Guerton B; Dupriez B; Bordessoule D; Fenaux P; Kiladjian JJ; Viallard JF; Brière J; Harrison CN; Green AR; Reilly JT
    Blood; 2006 Mar; 107(5):2098-100. PubMed ID: 16293597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
    Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
    Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
    Zhang S; Qiu H; Fischer BS; Li W; Duan L; Sun X; Xu W; Li J
    Leuk Lymphoma; 2008 Apr; 49(4):696-9. PubMed ID: 18398736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.
    Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F
    Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.